Stock SILCOPHL SILCO PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Silco Pharmaceuticals Limited

Equities

SILCOPHL

BD0495SILCO6

Pharmaceuticals

End-of-day quote Dhaka S.E.
Other stock markets
 03:30:00 27/06/2024 am IST 		5-day change 1st Jan Change
17.4 BDT -0.57% Intraday chart for Silco Pharmaceuticals Limited -1.69% -25.64%
01/05 Silco Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
07/02 Silco Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI

Valuation

Fiscal Period: June 2019 2020 2021 2022 2023
Capitalization 1 2,322 2,325 2,709 2,741 2,533
Enterprise Value (EV) 1 2,020 2,067 2,645 2,680 2,483
P/E ratio 10.8 x 28 x 32 x 32.5 x 36.6 x
Yield 0.81% 4.46% 3.83% 1.89% 1.23%
Capitalization / Revenue 2.53 x 3.17 x 4.51 x 4.9 x 5.45 x
EV / Revenue 2.2 x 2.82 x 4.4 x 4.79 x 5.34 x
EV / EBITDA 9.02 x 11.8 x 17.2 x 15.6 x 16.1 x
EV / FCF -115 x -39.5 x -18.6 x 74 x -213 x
FCF Yield -0.87% -2.53% -5.39% 1.35% -0.47%
Price to Book 1.06 x 1.04 x 1.19 x 1.2 x 1.09 x
Nbr of stocks (in thousands) 1,03,807 1,03,807 1,03,807 1,03,807 1,03,807
Reference price 2 22.36 22.40 26.10 26.40 24.40
Announcement Date 26/10/20 01/11/20 29/08/21 19/12/22 05/01/24
1BDT in Million2BDT
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 917.8 919 733.7 601.1 559.5 464.7
EBITDA 1 250.1 223.9 175.6 154 172.2 153.9
EBIT 1 162.9 141.5 96.96 79.39 97.48 67.18
Operating Margin 17.75% 15.39% 13.22% 13.21% 17.42% 14.46%
Earnings before Tax (EBT) 1 162.1 141.8 110.9 89.63 109 89.24
Net income 1 105.4 162.5 83.18 84.65 84.45 69.22
Net margin 11.48% 17.68% 11.34% 14.08% 15.09% 14.9%
EPS 2 1.488 2.077 0.8013 0.8154 0.8135 0.6668
Free Cash Flow 1 -13.7 -17.62 -52.35 -142.5 36.24 -11.67
FCF margin -1.49% -1.92% -7.14% -23.71% 6.48% -2.51%
FCF Conversion (EBITDA) - - - - 21.05% -
FCF Conversion (Net income) - - - - 42.91% -
Dividend per Share - 0.1818 1.000 1.000 0.5000 0.3000
Announcement Date 11/02/19 26/10/20 01/11/20 29/08/21 19/12/22 05/01/24
1BDT in Million2BDT
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 15.7 302 258 64.6 60.5 49.7
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -13.7 -17.6 -52.4 -143 36.2 -11.7
ROE (net income / shareholders' equity) 6.24% 8.28% 3.76% 3.75% 3.71% 3.01%
ROA (Net income/ Total Assets) 4.92% 3.75% 2.32% 1.85% 2.25% 1.53%
Assets 1 2,140 4,332 3,587 4,567 3,753 4,523
Book Value Per Share 2 24.60 21.00 21.60 21.80 22.00 22.30
Cash Flow per Share 2 0.2200 2.910 0.9800 0.5100 0.2600 0.3000
Capex 1 81.2 75.5 170 376 106 182
Capex / Sales 8.85% 8.21% 23.18% 62.63% 18.97% 39.15%
Announcement Date 11/02/19 26/10/20 01/11/20 29/08/21 19/12/22 05/01/24
1BDT in Million2BDT
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
SILCO PHARMACEUTICALS LIMITED Stock Silco Pharmaceuticals Limited
-25.64% 15.37M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.32% 815B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+44.05% 641B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.75% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+13.56% 314B
ABBVIE INC. Stock AbbVie Inc.
+10.68% 303B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.57% 242B
NOVARTIS AG Stock Novartis AG
+13.31% 218B
AMGEN INC. Stock Amgen Inc.
+8.48% 168B
PFIZER, INC. Stock Pfizer, Inc.
-2.81% 159B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SILCOPHL Stock
  4. Financials Silco Pharmaceuticals Limited